Levonorgestrel-releasing Intrauterine System - The discontinuing story

Gynecological Endocrinology

Volumn 25, Issue 10, 2009, Pages 668-673

  Ewies, Ayman A A ^a  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Levonorgestrel; Levonorgestrel releasing intrauterine system; LNG IUS

Indexed keywords

LEVONORGESTREL;

ADENOMYOSIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; HEALTH CARE PERSONNEL; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUAL CYCLE; MENSTRUATION; NONHUMAN; OVARY FUNCTION; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SEXUAL SATISFACTION; TREATMENT DURATION;

FEMALE; GREAT BRITAIN; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PATIENT SATISFACTION;

EID: 70350681823     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590903159656     Document Type: Review

References (42)

1. Halmesmaki K, Hurskainen R, Tiitinen A, Teperi J, Grenman S, Kivela A, Kujansuu E, Yliskoski M, Paavonen J. A randomized controlled trial of hysterectomy or levonorgestrel- releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod 2004;19:378-382.
2. British-National-Formulary. Intrauterine progestogen-only system. September 2007;54:430-431.
3. National-Institute-for-Health-and-Clinical-Excellence. Heavy Menstrual Bleeding. NICE Clinical Guidelines 44; 2007.
4. Nagrani R, Bowen-Simpkins P, Barrington JW. Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia?BJOG 2002;109:345-347.
5. Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, Nilsson CG. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998;316:1122-1126.
6. National-Institute-for-Health-and-Clinical-Excellence. Longacting reversible contraception. NICE Clinical Guidelines 30. London: RCOG; 2005.
7. Halmesmaki K, Hurskainen R, Teperi J, Grenman S, Kivela A, Kujansuu E, Tuppurainen M, Yliskoski M, Vuorma S, Paavonen J. The effect of hysterectomy or levonorgestrelreleasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. BJOG 2007;114:563-568.
8. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335-339.
9. Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil Steril 2005;83:398-404.
10. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
11. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-263.
12. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-77.
13. Daud S, Ewies AA. Levonorgestrel-releasing intrauterine system: why do some women dislike it? Gynecol Endocrinol 2008;24:686-690.
14. Cox M, Tripp J, Blacksell S. Clinical performance of levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5 year report. J Fam Plann Reprod Health Care 2002;28:73-77. (Pubitemid 34595935)
15. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, Park, Y, Lee, B. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008;198:373 e1-e7.
16. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004;111:1425-1428.
17. Bayer-plc. Electronic Medicines Compendium: LNG-IUS. Available from: http://emc.medicines.org.uk/medicine/1829/ SPC/Mirena/ [Accessed 6 March 2009].
18. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrelreleasing intrauterine device. Fertil Steril 1984;41:52-55.
19. RxList-The-Internet-Drug-Index. LNG-IUS. Available from: http://www.rxlist.com/mirena-drug.htm [Accessed 6 March 2009].
20. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F, Laatikainen T. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136-144.
21. Ilse JR, Greenberg HL, Bennett DD. Levonorgestrelreleasing intrauterine system and new-onset acne. Cutis 2008;82:158.
22. World-Health-Organization-(WHO). Medical Eligibility Criteria for Contraceptive Use. Geneva, Switzerland: WHO; 2000.
23. Fotherby K. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995;28:203-215.
24. Bayer-plc. Electronic Medicines Compendium: Norgeston. Available from: http://emc.medicines.org.uk/emc/assets/c/ html/displaydoc.asp?DocumentID= 1834#PHARMACOKIN ETIC-PROPS. [Accessed 24 December 2007].
25. Weiner E, Victor A, Johansson ED. Plasma levels of D-norgestrel after oral administration. Contraception 1976; 14:563-570.
26. Ratsula K, Toivonen J, Lahteenmaki P, Luukkainen T. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device. Contraception 1989;39:195-204.
27. Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562-567.
28. Nilsson CG, Johansson ED, Luukkainen T. A D-norgestrelreleasing IUD. Contraception 1976;13:503-514.
29. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-362.
30. RxList-The-Internet-Drug-Index. Alesse. Available from: http://www.rxlist.com/alesse-drug.htm. [Accessed 6 March 2009].
31. Wahab M, Al-Azzawi F. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2005;112:1455-1456.
32. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel- releasing IUD. Clin Endocrinol (Oxf) 1982;17:529-536.
33. Dennerstein L, Fotherby K, Burrows GD, Laby B, Wood C. Plasma levels of ethinyl oestradiol and norgestrel during hormone replacement therapy. Maturitas 1980;2:147-154.
34. RxList-The-Internet-Drug-Index. Seasonale. Available from: http://www.rxlist.com/seasonale-drug.htm. [Accessed 6 March 2009].
35. Custodia-Lora N, Novillo A, Callard IP. Effect of gonadal steroids on progesterone receptor, estrogen receptor, and vitellogenin expression in male turtles (Chrysemys picta). J Exp Zoolog A Comp Exp Biol 2004;301:15-25.
36. Okulicz WC. Temporal effects of progesterone inhibition of occupied nuclear oestrogen receptor retention in the rat uterus. J Endocrinol 1989;121:101-107.
37. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999;96:2907-2912.
38. Skrzypulec V, Drosdzol A. Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system - LNG-IUS. Coll Antropol 2008;32:1059-1068.
39. Gorgen H, Api M, Akca A, Cetin A. Use of the levonorgestrel- IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet 2008;279:835-840.
40. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. et al.Clinical outcomes and costswith the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-1463. (Pubitemid 38543736)
41. van Dongen H, van de Merwe AG, de Kroon CD, Jansen FW. The impact of alternative treatment for abnormal uterine bleeding on hysterectomy rates in a tertiary referral center. J Minim Invasive Gynecol 2009;16:47-51.
42. Lockhat FB, Emembolu JO, Konje JC. The efficacy, sideeffects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-793.